# reload+after+2024-01-22 20:44:27.404960
address1§2100 Powell Street
address2§Suite 720
city§EmeryVille
state§CA
zip§94608
country§United States
phone§510 848 5100
fax§510 848 1327
website§https://www.dynavax.com
industry§Drug Manufacturers—Specialty & Generic
sector§Healthcare
longBusinessSummary§Dynavax Technologies Corporation, a commercial stage biopharmaceutical company, focuses on developing and commercializing vaccines in the United States. It markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe. The company also manufactures and sells CpG 1018, the adjuvant used in HEPLISAV-B. Dynavax Technologies Corporation has a collaboration agreement with Valneva Scotland Limited; Zhejiang Clover Biopharmaceuticals, Inc.; Clover Biopharmaceuticals (Hong Kong) Co., Limited; Biological E. Limited; PT Bio Farma; Medigen Vaccine Biologics; and Serum Institute of India Pvt. Ltd. The company was formerly known as Double Helix Corporation and changed its name to Dynavax Technologies Corporation in September 1996. Dynavax Technologies Corporation was incorporated in 1996 and is headquartered in Emeryville, California.
fullTimeEmployees§351
companyOfficers§[{'maxAge': 1, 'name': 'Mr. Ryan  Spencer', 'age': 45, 'title': 'CEO & Director', 'yearBorn': 1978, 'fiscalYear': 2022, 'totalPay': 1251235, 'exercisedValue': 0, 'unexercisedValue': 2703367}, {'maxAge': 1, 'name': 'Mr. David F. Novack', 'age': 61, 'title': 'President & COO', 'yearBorn': 1962, 'fiscalYear': 2022, 'totalPay': 925598, 'exercisedValue': 0, 'unexercisedValue': 1779099}, {'maxAge': 1, 'name': 'Ms. Kelly  MacDonald', 'age': 39, 'title': 'Senior VP & CFO', 'yearBorn': 1984, 'fiscalYear': 2022, 'totalPay': 674266, 'exercisedValue': 0, 'unexercisedValue': 355249}, {'maxAge': 1, 'name': 'Dr. Robert  Janssen', 'age': 69, 'title': 'Chief Medical Officer and Senior VP of Clinical Development, Medical & Regulatory Affairs', 'yearBorn': 1954, 'fiscalYear': 2022, 'totalPay': 789757, 'exercisedValue': 35662, 'unexercisedValue': 599218}, {'maxAge': 1, 'name': 'Mr. Justin  Burgess', 'title': 'Principal Accounting Officer & Controller', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. Jeff P. Coon', 'age': 60, 'title': 'CHRO and Senior VP of Human Resources & Administration', 'yearBorn': 1963, 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. Paul  Cox', 'title': 'VP of Investor Relations & Corporate Communications', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. John  Slebir', 'title': 'Senior VP & General Counsel', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. Donn  Casale', 'title': 'Chief Commercial Officer', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Dr. Dong  Yu', 'title': 'Senior Vice President of Vaccine Research', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}]
auditRisk§4
boardRisk§5
compensationRisk§3
shareHolderRightsRisk§7
overallRisk§5
governanceEpochDate§1704067200
compensationAsOfEpochDate§1672444800
maxAge§86400
priceHint§2
payoutRatio§0.0
beta§1.294
priceToSalesTrailing12Months§5.275229
currency§USD
dateShortInterest§1702598400
forwardEps§0.31
exchange§NMS
quoteType§EQUITY
shortName§Dynavax Technologies Corporatio
longName§Dynavax Technologies Corporation
firstTradeDateEpochUtc§1077201000
timeZoneFullName§America/New_York
timeZoneShortName§EST
uuid§1098d91b-0224-393f-80a2-54d47c7c6e9b
gmtOffSetMilliseconds§-18000000
targetHighPrice§27.0
targetLowPrice§21.0
targetMeanPrice§25.0
targetMedianPrice§26.0
recommendationMean§1.8
recommendationKey§buy
numberOfAnalystOpinions§4
quickRatio§14.174
earningsGrowth§-0.765
grossMargins§0.62966
ebitdaMargins§0.22027999
trailingPegRatio§None
